Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vivesto AB ( (SE:VIVE) ) has issued an announcement.
Vivesto’s board has proposed a reverse share split that would consolidate 100 existing shares into one new share, cutting the total number of shares from 1,107,136,910 to 11,071,369, with shareholders holding non-divisible lots to receive cash proceeds from the sale of excess shares. The board is also seeking approval to reduce the company’s share capital from SEK 110,713,691 to SEK 11,071,369 by reallocating SEK 99,642,322 to unrestricted equity, a move aimed at aligning the capital structure with Vivesto’s operational and capital needs following recent rights and directed share issues, without changing total equity.
The most recent analyst rating on (SE:VIVE) stock is a Hold with a SEK0.08 price target. To see the full list of analyst forecasts on Vivesto AB stock, see the SE:VIVE Stock Forecast page.
More about Vivesto AB
Vivesto AB is a Swedish development-stage biopharmaceutical company focused on creating new treatment options for hard-to-treat cancers with significant unmet medical needs and market potential. Its pipeline includes Cantrixil, in development for blood cancers, and the veterinary oncology candidate Paccal Vet, being tested in clinical trials for dogs with splenic hemangiosarcoma and in dose-finding studies in cats with solid tumors.
Average Trading Volume: 1,508,377
Technical Sentiment Signal: Sell
Current Market Cap: SEK85.91M
For a thorough assessment of VIVE stock, go to TipRanks’ Stock Analysis page.